News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
16,171 Results
Type
Article (312)
Company Profile (1)
Press Release (15858)
Section
Business (8806)
Career Advice (11)
Deals (1019)
Drug Development (1346)
Employer Resources (4)
FDA (219)
Job Trends (415)
News (10660)
Policy (430)
Tag
Academia (21)
Allergies (5)
Alliances (343)
ALS (2)
Alzheimer's disease (29)
Antibody-drug conjugate (ADC) (7)
Approvals (228)
Artificial intelligence (4)
Autoimmune disease (3)
Automation (2)
Best Places to Work (405)
Biosimilars (2)
Bladder cancer (3)
Brain cancer (1)
Breast cancer (12)
Cancer (157)
Cardiovascular disease (6)
Career advice (8)
CAR-T (3)
Cell therapy (5)
Cervical cancer (1)
Clinical research (1221)
Collaboration (10)
Compensation (4)
COVID-19 (33)
CRISPR (3)
C-suite (3)
Cystic fibrosis (17)
Data (187)
Depression (2)
Diabetes (10)
Diagnostics (212)
Digital health (2)
Drug discovery (1)
Duchenne muscular dystrophy (6)
Earnings (8779)
Employer resources (4)
Events (1905)
Executive appointments (3)
FDA (336)
Fibrodysplasia Ossificans Progressiva (1)
Funding (10)
Gene editing (3)
Gene therapy (7)
GLP-1 (13)
Government (57)
Guidances (92)
Healthcare (585)
Huntington's disease (2)
IgA nephropathy (1)
Immunology and inflammation (7)
Indications (3)
Infectious disease (37)
Inflammatory bowel disease (5)
Intellectual property (2)
Interviews (3)
IPO (870)
Job creations (24)
Job search strategy (8)
Layoffs (9)
Legal (52)
Liver cancer (2)
Lung cancer (19)
Lymphoma (24)
Management (3)
Manufacturing (2)
MASH (1)
Medical device (473)
Medtech (476)
Mergers & acquisitions (165)
Metabolic disorders (16)
Multiple sclerosis (4)
Neurodegenerative disease (1)
Neuropsychiatric disorders (3)
Neuroscience (48)
NextGen: Class of 2026 (110)
Non-profit (111)
Obesity (5)
Opinion (1)
Ovarian cancer (17)
Pain (1)
Pancreatic cancer (2)
Parkinson's disease (1)
Patents (3)
Patient recruitment (5)
Peanut (2)
People (450)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase 1 (344)
Phase 2 (519)
Phase 3 (492)
Pipeline (354)
Postmarket research (30)
Preclinical (155)
Prostate cancer (2)
Radiopharmaceuticals (7)
Rare diseases (26)
Real estate (39)
Recruiting (1)
Regulatory (370)
Reports (3)
Research institute (35)
Resumes & cover letters (3)
Rett syndrome (2)
RSV (3)
Schizophrenia (2)
Series A (2)
Series B (2)
Sickle cell disease (1)
Spinal muscular atrophy (6)
Sponsored (1)
Startups (24)
Stomach cancer (1)
Vaccines (22)
Women's health (2)
Date
Last 7 days (8)
Last 30 days (22)
Last 365 days (1039)
2026 (34)
2025 (1054)
2024 (995)
2023 (1253)
2022 (3567)
2021 (1593)
2020 (1390)
2019 (960)
2018 (773)
2017 (579)
2016 (359)
2015 (694)
2014 (439)
2013 (213)
2012 (247)
2011 (261)
2010 (265)
Location
Africa (4)
Arizona (5)
Asia (721)
Australia (77)
California (357)
Canada (98)
China (24)
Colorado (22)
Connecticut (15)
Delaware (22)
Europe (1688)
Florida (47)
Georgia (10)
Illinois (25)
India (1)
Indiana (26)
Japan (2)
Kansas (4)
Kentucky (3)
Louisiana (4)
Maine (5)
Maryland (35)
Massachusetts (262)
Michigan (17)
Minnesota (26)
Missouri (1)
Montana (2)
Nevada (1)
New Hampshire (6)
New Jersey (138)
New York (88)
North Carolina (35)
Northern California (158)
Ohio (9)
Pennsylvania (79)
South America (16)
Southern California (165)
Texas (42)
United States (1330)
Utah (17)
Virginia (9)
Washington State (28)
Wisconsin (3)
16,171 Results for "253".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
January 7, 2026
·
4 min read
Press Releases
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
October 19, 2025
·
5 min read
Drug Development
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new clinical data from its ongoing KT-253 Phase 1 trial.
June 1, 2024
·
9 min read
Drug Development
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics, Inc. announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial will be presented at the American Society of Clinical Oncology Annual Meeting, taking place from May 31 – June 4, 2024, in Chicago, Illinois.
May 23, 2024
·
8 min read
Drug Development
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
Kymera Therapeutics, Inc. has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253.
May 19, 2023
·
6 min read
FDA
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
Kymera Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia (AML).
June 22, 2023
·
6 min read
Aptose Provides Update on APTO-253 Program
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253.
December 20, 2021
·
4 min read
Drug Development
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
Kymera Therapeutics, Inc. presented preclinical data showing that KT-253, a novel MDM2 degrader, inhibited tumor growth as single agent and in combination with venetoclax in AML xenograft models.
December 11, 2022
·
8 min read
U.S. Home Healthcare Market To Cross Valuation Of US$ 253.8Bn By 2030
According to Nova one advisor, the U.S. Home Healthcare market size was valued at US$ 132.9 billion in 2021 and is expected to hit US$ 253.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.50% from 2022 to 2030.
June 21, 2022
·
7 min read
Bio NC
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA®.
June 24, 2022
·
4 min read
1 of 1,618
Next
